` 6990 (Sichuan Kelun-Biotech Biopharmaceutical Co Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

6990
vs
Hang Seng (Hong Kong)

Over the past 12 months, has significantly outperformed Hang Seng (Hong Kong), delivering a return of 82% compared to the Hang Seng (Hong Kong)'s 25% growth.

Stocks Performance
6990 vs Hang Seng (Hong Kong)

Loading
6990
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com

Performance Gap
6990 vs Hang Seng (Hong Kong)

Loading

Over the past 12 months, has outperformed Hang Seng (Hong Kong) by 57.59%.

6990
Hang Seng (Hong Kong)
Difference
www.alphaspread.com

Performance By Year
6990 vs Hang Seng (Hong Kong)

Loading
6990
Hang Seng (Hong Kong)
Add Stock

Competitors Performance
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd vs Peers

Hang Seng (Hong Kong)
6990
ABBV
AMGN
GILD
VRTX
Add Stock

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Glance View

Market Cap
72.5B HKD
Industry
Biotechnology

Nestled in the vibrant economic landscape of China, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. emerges as a prominent figure within the biopharmaceutical industry. Founded as a subsidiary of the larger pharmaceutical umbrella of Sichuan Kelun Pharmaceutical Co., Ltd., the company leverages its parent's extensive network and expertise to carve its niche in an ever-evolving market. Kelun-Biotech focuses on innovation in drug development, particularly in biologics and complex generics. This focus allows it to produce high-value pharmaceuticals that address urgent medical needs, spanning across treatments for oncology, immunological disorders, and other critical health segments. Its dedication to cutting-edge research and development is evident in the substantial investments it channels into its laboratories and collaborations with leading research institutions, both domestically and internationally. The company's revenue model pivots around the commercialization of its proprietary drugs and partnerships with multinational pharmaceutical firms, where it contributes its research prowess to joint ventures. By positioning itself as a leader in the biologics sector, Kelun-Biotech capitalizes on the growing demand for biosimilars and innovative therapies in the global market. Its strategy to penetrate international markets is further bolstered by strategic alliances and compliance with stringent global regulatory approvals, enhancing its credibility and reach. These endeavors not only drive its revenue growth but also reinforce its mission to deliver high-quality, affordable healthcare solutions worldwide, making Kelun-Biotech an influential player in addressing global health challenges through pharmaceutical excellence.

Intrinsic Value
161.86 HKD
Overvaluation 49%
Intrinsic Value
Price
S
Back to Top